Cancer Therapy

You have full text access to this OnlineOpen article

BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance

  1. Hong Zhang†,*,
  2. Laura Neely,
  3. Karen Lundgren,
  4. Yong-Ching Yang,
  5. Rachel Lough,
  6. Noel Timple,
  7. Francis Burrows

Article first published online: 12 AUG 2009

DOI: 10.1002/ijc.24825

Issue

International Journal of Cancer

International Journal of Cancer

Volume 126, Issue 5, pages 1226–1234, 1 March 2010

Additional Information

How to Cite

Zhang, H., Neely, L., Lundgren, K., Yang, Y.-C., Lough, R., Timple, N. and Burrows, F. (2010), BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int. J. Cancer, 126: 1226–1234. doi: 10.1002/ijc.24825

Author Information

  1. Biogen Idec, 5200 Research Place, San Diego, CA

  1. †

    Fax: (858) 795-9661

*Biogen Idec, 5200 Research Place, San Diego, CA, USA

Publication History

  1. Issue published online: 27 DEC 2009
  2. Article first published online: 12 AUG 2009
  3. Accepted manuscript online: 12 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 30 JUL 2009
  5. Manuscript Received: 12 MAR 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (629K)

References

  • 1
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006; 103: 17408–13.
  • 2
    Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005; 56: 115–25.
  • 3
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48–58.
  • 4
    Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Therapeut 2000; 85: 217–29.
  • 5
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–9.
  • 6
    Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468–85.
  • 7
    Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003; 304: 1085–92.
  • 8
    Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004; 1: 27–42.
  • 9
    Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347–59.
  • 10
    Johnson WW. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol 2002; 24: 501–14.
  • 11
    Fischer V, Einolf HJ, Cohen D. Efflux transporters and their clinical relevance. Mini Rev Med Chem 2005; 5: 183–95.
  • 12
    Webb M, Brun M, McNiven M, Le Couteur D, Craft P. MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 1998; 102: 710–7.
  • 13
    Shtil AA, Azare J. Redundancy of biological regulation as the basis of emergence of multidrug resistance. Int Rev Cytol 2005; 246: 1–29.
  • 14
    Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91: 1940–9.
  • 15
    Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 2003; 102: 269–75.
  • 16
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005; 65: 10006–15.
  • 17
    Process for preparing 17-allyl amino geldanamycin (17-AAG) and other ansamycins. Pat, no. WO 0,302,6571. 2002.
  • 18
    Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, et al. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 2007; 50: 2767–78.
  • 19
    Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 2000; 1: 85–99.
  • 20
    Mirski SE, Gerlach JH, Cole SP. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987; 47: 2594–8.
  • 21
    Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, Dijkmans BA, Peters GJ, Jansen G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 2003; 278: 6680–6.
  • 22
    Chauvier D, Kegelaer G, Morjani H, Manfait M. Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. J Pharm Sci 2002; 91: 1765–75.
  • 23
    Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61: 4003–9.
  • 24
    Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000; 60: 3940–6.
  • 25
    Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002; 2: 3–24.
  • 26
    Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003; 15: 419–24.
  • 27
    Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004; 82: 488–99.
  • 28
    Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Topics Med Chem 2006; 6: 1205–14.
  • 29
    Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007; 13: 1775–82.
  • 30
    Pacey S, Banerji U, Judson I, Workman P. Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006: 331–58.
  • 31
    Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3: 377–83.
  • 32
    Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J, Motzer RJ. A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006; 24: 543–6.
  • 33
    Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008; 14: 7940–6.
  • 34
    Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med Res Rev 2005; 25: 453–72.
  • 35
    Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65: 2577–82.
  • 36
    McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO, Erlichman C. P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 2008; 68: 7419–27.
  • 37
    Lundgren K, Zhang H, Brekken J, Huser N, Lough R, Timple N, Busch D, Neely L, Sensintaffer J, Yang C, McKenzie A, Friedman J, et al. BIIB021, an orally available, small molecule inhibitor of the heat shock protein, Hsp90. Mol Cancer Ther 2009; 8: 921–9.
View Full Article (HTML) Get PDF (629K)